EXPERIENCE OF USING BEDAQUILINE IN THE MULTIMODALITY THERAPY OF TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION

The goal of the study: to evaluate efficiency and safety of the anti-tuberculosis drug of bedaquiline in the multimodality therapy of patients with HIV-associated tuberculosis with multiple/extensive drug resistance (MDR/XDR).Materials and methods. 14 patients were treated with the regimens containing bedaquiline. The majority of patients (12; 85.7%) received antiretroviral therapy. 11 (78.6%) patients were diagnosed with the generalized form of tuberculosis affecting two organs and more. All 14 patients were infectious: 2 had MDR TB and 12 had XDR TB, and of them, 11 had XDR TB with resistance to 8-10 anti-tuberculosis drugs.Results. 12 out of 14 patients completed the intensive phase with administration of bedaquiline. By the end of the first month of treatment intoxication symptoms disappeared in 50.0% of patients, and by the end of the second month, they remitted in 83.5%. The positive X-ray changes were observed in 50% of patients, and they manifested through the partial resolution of focal infiltrate changes in the lungs. Cessation of bacillary excretion was documented by the end of the second month in 6 patients, by the end of the 3rd month in 1 patient, by the end of the 6th month in 3 patients, totally in 10 out of 12 patients (83.3%). During treatment, all patients had an electrocardiogram, and none of them had prolongation of QT interval